chrisvoncsefalvay/vaers-outcomes huggingface dataset:
When I caught covid I first started feeling really really tired. Then I started coughing. I thought I had pneumonia because of my symptoms. I waited until it got bad to where I couldn't hardly walk. It felt like I was going septic. I had a fever. I went to the hospital where I was admitted. I was so sick I couldn't hold my eyes open, and I could barley move my body. I was septic and had pneumonia before. The doctor's tested me and said I didn't have pneumonia, but I did have covid. I still have a sore in my nose and the side of my mouth. I'm not coughing as bad anymore. When I got out of the hospital I couldn't stop coughing for about 4 weeks. My hair was also getting thin. I was achy and tired, but I'm doing a lot better now.
Mother call describing large red, raised area by injection site Left thigh 3 inches by 4 inches.  Mother was advised to call primary care physician for further instructions.
Fingers had minor peeling skin; Hypersensitivity reaction; Rash; Itchy red circular patch at injection site (left arm); Itchy red circular patch at injection site (left arm); red, itchy hive-like spots on right hand (mainly 3 fingers) and the next day on couple fingers of left hand; Tingly feeling on fingers; Scratching left arm w/ right hand; This spontaneous case was reported by a consumer and describes the occurrence of SKIN EXFOLIATION (Fingers had minor peeling skin), URTICARIA (red, itchy hive-like spots on right hand (mainly 3 fingers) and the next day on couple fingers of left hand), PARAESTHESIA (Tingly feeling on fingers), SCRATCH (Scratching left arm w/ right hand) and HYPERSENSITIVITY (Hypersensitivity reaction) in a 23-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 042B212A and 034C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 01-May-2021 at 2:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-May-2021 at 1:20 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 09-May-2021, the patient experienced URTICARIA (red, itchy hive-like spots on right hand (mainly 3 fingers) and the next day on couple fingers of left hand), SCRATCH (Scratching left arm w/ right hand) and RASH (Rash). 09-May-2021, the patient experienced PARAESTHESIA (Tingly feeling on fingers). 09-May-2021, the patient experienced VACCINATION SITE PRURITUS (Itchy red circular patch at injection site (left arm)) and VACCINATION SITE ERYTHEMA (Itchy red circular patch at injection site (left arm)). On 09-May-2021 at 1:00 PM, the patient experienced HYPERSENSITIVITY (Hypersensitivity reaction). On an unknown date, the patient experienced SKIN EXFOLIATION (Fingers had minor peeling skin). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) from 12-May-2021 to 13-May-2021 for Adverse event, at an unspecified dose and frequency. On 19-May-2021, SKIN EXFOLIATION (Fingers had minor peeling skin), URTICARIA (red, itchy hive-like spots on right hand (mainly 3 fingers) and the next day on couple fingers of left hand), PARAESTHESIA (Tingly feeling on fingers), HYPERSENSITIVITY (Hypersensitivity reaction), RASH (Rash), VACCINATION SITE PRURITUS (Itchy red circular patch at injection site (left arm)) and VACCINATION SITE ERYTHEMA (Itchy red circular patch at injection site (left arm)) had resolved. At the time of the report, SCRATCH (Scratching left arm w/ right hand) outcome was unknown.            Concomitant product use was not provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 11-Jun-2021: Events added, outcome and reporter causality updated.
patient received Covid 19 vaccine Johnston and Johnston on 03/13/2021, became positive for covid on 04/13/2021, went to hosp, admitted
Vaccinator hit a vein instead of the muscle; Blood shot out at the injection site; A spontaneous report was received from a physician concerning a patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced blood shooting out at the injection site and vaccinator hit a vein instead of the muscle.  The patient's medical history was not provided. No relevant concomitant medications were reported.    On an unknown date, the patient received their first of two planned doses of mRNA-1273 for prophylaxis of COVID-19 infection.   On an unknown date, the patient was administered the vaccine and immediately after, blood shot out onto the patient's leg. The reporter assumed the vaccinator hit a vein instead of a muscle. No treatment information was provided.  The events, blood shot out at the injection site and vaccinator hit a vein instead of the muscle, were considered resolved.; Reporter's Comments: This report refers to a case of incorrect route of product administration for mRNA-1273 and concerns a patient (age and gender unknown), who experienced the event of injection site hemorrhage. The event occurred the same day after the first and only dose of mRNA-1273 vaccine administration. Based on the current available information and the event was likely due to incorrect route of administration, the event is assessed as unlikely related to mRNA-1273 vaccine.
2x3 inch itchy, mildly painful red oval on right arm started on day 8 after first vaccine.  Skin temperature in red area is 96F; 89F in control area.  Also experienced swollen lymph nodes on right armpit four days after first vaccine.
body aches; my legs didn't want to work; was out of it, & bedridden; high temperature of 102.8F; severe headaches; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (body aches), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (my legs didn't want to work), BEDRIDDEN (was out of it, & bedridden), PYREXIA (high temperature of 102.8F) and HEADACHE (severe headaches) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016M20A) for COVID-19 vaccination.     The patient's past medical history included Shaking of hands on 04-Jan-2021 and Numbness mouth (mouth starts getting numb, like and  been to the dentist & starting coming out of the Novocaine) on 04-Jan-2021.    On 17-Feb-2021 at 1:45 PM, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Feb-2021, the patient experienced MYALGIA (body aches), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (my legs didn't want to work), BEDRIDDEN (was out of it, & bedridden), PYREXIA (high temperature of 102.8F) and HEADACHE (severe headaches). At the time of the report, MYALGIA (body aches), LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (my legs didn't want to work), BEDRIDDEN (was out of it, & bedridden), PYREXIA (high temperature of 102.8F) and HEADACHE (severe headaches) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 18-Feb-2021, Body temperature: 102.8 (High) high temperature of 102.8F.         Patient usually an active person and take long hikes with daughter, & I kayak.  Concomitant medications was not reported. Treatment medications was not reported.   This case was linked to MOD-2022-438710, MOD-2022-438597 (Patient Link).
fever; tiredness; aching; feeling yucky; This case was reported by a consumer via interactive digital media and described the occurrence of fever in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Previously administered products included Shingles vaccine with an associated reaction of pain (1st dose received on an unknown date and experienced a little soreness, refer case US2021AMR196275).   On an unknown date, the patient received the 2nd dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced fever, tiredness, pain and feeling abnormal. Rechallenge with Shingles vaccine was positive. On an unknown date, the outcome of the fever, tiredness and pain were unknown and the outcome of the feeling abnormal was recovered/resolved.   It was unknown if the reporter considered the fever, tiredness, pain and feeling abnormal to be related to Shingles vaccine.  Additional details were provided as follows: The case was reported by the patient for himself/herself. The age at vaccination was not reported. The patient got the second dose which caused a fever over 102 degree Fahrenheit, tiredness, aching and just plain feeling yucky for 2 days.  The patient said, he/she would not get shingles.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR196275:same reporter
about 1 min after receiving the shot, patient feel uneasy, a bit of dizziness and sweating. Patient did not loss consciousness and  recovered after 10 to 15mins of hydration and sitting
Numbness,tingling sensation-I left-side-of-face.??Started-35-hours-after-injection. Lasted3-4hours.-no-other-neurological-symptoms- Took-aspirin-as-symptoms-subsided.
pt describes area where shot was given was itching p/getting vax;devel 3 small pustules surrounding shot site on rt lateral arm;this occurred 3-4 days p/shot;pt kept a bandaid over the site for 24hr;
inappropriate schedule of vaccine administereddose 1- 20210111, dose 2- 20210125; Fever of 104.0; chills; muscle aches; headache; dizziness; body aches; pain at site of vaccination; This is a spontaneous report from a non-contactable healthcare professional, the patient. A 24-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 25Jan2021 at 14:00 (at the age of 24-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient previously received cephalosporin nos (MANUFACTURER UNKNOWN) on an unspecified date for an unspecified indication and experienced drug allergy. Concomitant medication included spironolactone (MANUFACTURER UNKNOWN) from an unknown date, for an unspecified indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 11Jan2021 at 14:00 (at the age of 24-year-old) as  a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Jan2021 the patient experienced fever of 104.0, chills, muscle aches, headache, dizziness, body aches and pain at site of vaccination. On 25Jan2021 the body temperature of the patient was measured and the result was 104.0 (unspecified unit). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the adverse events. The clinical outcomes of the events fever of 104.0, chills, muscle aches, headache, dizziness, body aches and pain at site of vaccination were recovered on an unknown date in 2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
When shot was being placed into left shoulder, it felt "too deep" which prompted me to tighten muscle during injection. I receive yearly flu shots, etc. I never felt this particular sensation before. I had a bruise in the area for well over a week, a very sore arm which I could not lay on for a couple of days. Pain traveled up to shoulder/collarbone soreness and neck soreness. I still have shoulder soreness/a Chinese, L collarbone (underneath,  perhaps swollen lymph nodes) and neck soreness. Feels as if shot inadvertently placed in L subdeltoid bursa, which is sore to touch. Now L elbow aches at times in past 2 weeks,  and left wrist feels achy at times in past 2 days.
pt has 10-20 erythematous macular papular lesion on back & buttocks,  w/scabs, & 1 appears vesicular-felt to be chickenpox-lesions p/2-3days;
Information has been received from a website concerning thousands of other young girls who on unspecified dates were vaccinated with a dose of GARDASIL (lot # not reported). The girls have experienced "life-destroying side effects" or death following their HPV vaccines. Life-destroying side effects were considered to be immediately life-threatening. This is one of two reports from the same source. No further information is available.
This spontaneous report as received from a physician via company representative refers to a patient of unknown age and gender. The patient's medical history and current conditions were not provided. On an unknown date, the patient was vaccinated with RECOMBIVAX HB (lot #, expiration date, dose and route were not reported). On an unknown date, the patient was vaccinated with RECOMBIVAX HB (lot #, expiration date, dose and route were not reported). On an unknown date, the patient had negative titers after receiving RECOMBIVAX HB. The outcome of negative titers was unknown. The relatedness between adverse event and RECOMBIVAX HB was not reported. Additional information is not expected due to contact Health Care Professional was given.
Patient felt dizzy for a short period of time; 911 was contacted; patient was not hospitalized; blood pressure was increased slightly when 911 arrived.
pt devel hive like rash over trunk & extremities 5min p/vax;
Contracted Covid-19 in mid-October (tested positive); lack of drug efficacy; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Contracted Covid-19 in mid-October (tested positive)) and DRUG INEFFECTIVE (lack of drug efficacy) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016B21A and 023M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In October 2021, the patient experienced COVID-19 (Contracted Covid-19 in mid-October (tested positive)) and DRUG INEFFECTIVE (lack of drug efficacy). At the time of the report, COVID-19 (Contracted Covid-19 in mid-October (tested positive)) had resolved and DRUG INEFFECTIVE (lack of drug efficacy) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In October 2021, SARS-CoV-2 test: negative (Negative) tested negative two weeks later.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications was reported,. No treatment drug details was reported. Company comment: This case concerns a 66-years-old male patient, with no medical history reported in this case, who experienced the non-serious AESI of COVID-19. Additionally, Drug ineffective was also reported.  The events were reported to occur approximately 8 months after the administration of a proper schedule of vaccination with the mRNA-1273 vaccine (29 days between doses) and, at the time of the report, the outcome was reported as Recovered/Resolved.  The causality is not applicable as per the nature of the event.  No further information on clinical course, diagnosis or treatment was provided.  The rechallenge is not applicable as the events occurred after the administration of the second dose of the mRNA-1273 vaccine.  The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This case concerns a 66-years-old male patient, with no medical history reported in this case, who experienced the non-serious AESI of COVID-19. Additionally, Drug ineffective was also reported.  The events were reported to occur approximately 8 months after the administration of a proper schedule of vaccination with the mRNA-1273 vaccine (29 days between doses) and, at the time of the report, the outcome was reported as Recovered/Resolved.  The causality is not applicable as per the nature of the event.  No further information on clinical course, diagnosis or treatment was provided.  The rechallenge is not applicable as the events occurred after the administration of the second dose of the mRNA-1273 vaccine.  The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Patient returned to the store around 6pm the evening she received the shot 12-14-16 and reported significant swelling and pain in the arm she received the shot. Pt stated this reaction has happened in the past and symptoms improved 12/15/16 after using ice/ibuprofen.
On March 23, four days after the vaccine injection, I developed a burning pain in my Left arm and temperature of 100.2 . An area about 5 inches in diameter was dark red and hot to touch. This  area was well below the injection site, approximately 6 inches below the injection site.  My doctor advised a cold compress and Benadryl. The area remained hot, red and itchy for 5 days. Temperature elevation lasted 24 hours.
Approx 2 minutes after pneumococcal vaccine at 1125 a.m., pt c/o dizziness. Pt's face turned red. Pt c/o chest tightness and back pain 11/10. Doctor notified. New orders received. 25 mg Benadryl IV and 4 mg morphine IV given. Stat EKG done. Pain, flushing and dizziness lessened in 15 minutes to 5/10 back pain. Pain in R abd around to back reported around 1215 at 4/10. At 1300 Pt reported R abd pain 2/10.
sore arm; This is a spontaneous report from two contactable physicians (patient) via Pfizer Sales Representative. Both physicians reported same event for 2 patients. This is second of 2 report. A 71-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via unspecified route of administration on unspecified date at single dose for COVID-19 immunization. Medical history and concomitant medication were not reported. It was reported patient had a sore arm. The two physicians both had the vaccine at the same time. The adverse event took place after Pfizer Product use. Outcome of the event was unknown.   Information on lot/batch number has been requested. ; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021044461 same product/AE/ reporter, different patient
The reporter is the parent and is a practicing D.O. who states that this report was also given by telephone to manufacturer sometime during the week of 10-10-05. The reporter called this report to CDC, who is entering this info on behalf of the reporter.  Child began to experience right hand numbness on 8-21-05.  This progressed to left hand within 2 weeks.  MRI done 9-8-05, showed demyelination at C2-C3.  Neuro consult on 9-9-05, LP and blood work done.  On 9-20-05, upper body symptoms seems to peak.  Repeat MRI on 9-22-05 showed increase in c2-C3 lesion, but a decrease in the update of contrast dye seemed to indicate that the lesion was improving.  Then on 9-30-05, lower leg numbness presented bilaterally, and a third MRI on 10-5-05 showed a second demyelination at C3-C4.  A five day Steroid taper was initiated on 10-6-05 and improvement was noted on about 10-8-05.  As of this report, child is slowly improving, and the reporter has received neuro consult with neurologist to consider beta-interferon tx.  Medical records were requested to be sent and reporter states that he will send the records on 10-18-05.
Information has been received on 17-FEB-2017 from a female physician via a company representative referring to a 12-year-old male patient. The patient's medical history included "Behavioral issues". Concomitant medication and drug reactions/allergies were reported as "unknown" by the reporter. The physician reported that the patient who had been administered a single shot of GARDASIL 9 (strength and site not reported; lot number M031557 and expiration date 17-APR-2019) intramuscularly for prophylaxis, had developed a "tick" that "started to occur occasionally but now occurs all the time." It was also noted that the patient had been administered MENACTRA and BOOSTRIX on the same day the GARDASIL 9 was administered on 20-JAN-2017.  The patient had received the shot of GARDASIL 9 on 20-JAN-2017 but the specific date of adverse event (AE) onset was unknown by reporter.  At the time of report, 17-FEB-2017, medical attention was not sought, no laboratory studies performed, no treatment given for the adverse event. At the time of the call the patient did not recover but is expected to meet with his physicians (as reported) on 20-FEB-2017. All quoted information is included as stated and no other information was given at the time of the call. Additional information has been requested.
Hot flashes in face (no fever) coldness weakness, upset stomach, slight discomfort in head, very shortness of breath (small amount) palpitation of heart (still feel it a little). 12-7-10 pain in muscle where shot given. 12-7-10 still feel shot not given in muscle flushed in face little of a palpitation of heart 12-10-10.
1-2 mm erythema, vesicular lesions left back and mid spine 1 day after vaccine - scabbed up very quickly - no vesicles now and patient with temp 99.1.
sick with flu like symptoms; Initial information received on 10-Oct-2020 regarding an unsolicited valid non-serious case from a consumer/non-healthcare professional.  This case involves a patient who was sick with flu like symptoms (influenza like illness), while he/she received vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment, past vaccination and family history were not provided. Concomitant medication were not reported.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number not reported) via an unknown route at an unknown administration site as prophylactic vaccination.  On an unknown date, the patient was sick with flu like symptoms (influenza like illness) within 24-48 hours following the administration of INFLUENZA VACCINE. It was also reported that the patient thought that he/she was going to die. and the event lasted for 4 weeks.  Laboratory details were not reported.  It was not reported if the patient received any corrective treatment.  The event outcome was unknown at the time of reporting.  There will be no information available on batch number for this case.
This literature report concerns a series of 10 cases of fatalities after H1N1 vaccinations. These 10 cases involved 2 children, 7 adults and 1 elderly reported. This case (3 of 10) concerns a 19-year-old female patient, who had a medical history of Rett syndrome and severe muscle wasting/physical disability. The patient died of Bilateral pneumonia and respiratory failure, nine days after H1N1 vaccination (type: monovalent inactivated, split-virus or subunit vaccine; manufacture: unknown). Reporters comment: VAERS (Vaccine Adverse Event Reporting System) received 13 reports of deaths occurring after receipt of H1N1 vaccine; 3 deaths occurred after receipt of LAMV (live, attenuated monovalent vaccine) and 10 after receipt of MIV (monovalent inactivated, split-virus or subunit vaccines). In 9 of these deaths, significant underlying illness (including illness that might be indication for vaccination) was present; 1 death resulted from a motor vehicle crash, and the remaining 3 deaths await review of final autopsy results or death certificates by CDC (Centers for Disease Control).
pt recvd vax 25AUG72 & devel convuls & was hospitalized & dx as having viral encephalitis; pt subsequently discharged from hosp; no further details were  provided;
Approximately 3-4 weeks after second dose, developed symptoms of Graves? disease and was diagnosed with Graves? disease early June.